Medicaid

Medicaid

GLP-1 coverage · Rules read August 2026

AGAmerican GLP, Publisher · Who writes this site

With Medicaid, where you live decides almost everything. Federal law lets states exclude weight-loss drugs, and most do.

The number of states covering GLP-1s for obesity is going down, not up. Four states ended coverage between October 2025 and January 2026.

What the rules actually say

What to do

1. Read the denial notice for your own deadline

   Federal rules cap the window at 90 days from the date the notice was mailed, and states may allow less. The date on your notice binds you, not the federal ceiling.

2. Request a fair hearing in writing

   Name the denial and its date, say you are requesting a fair hearing, and keep a copy of what you sent and when. Ask for an expedited hearing if waiting would harm you.

3. Check whether you are in managed care first

   If your coverage runs through a managed care plan you may have to finish that plan's internal appeal before the state hearing. Ask which applies to you.

The states we have read for ourselves

The counts above come from a national survey. Below are the states whose own preferred drug lists, provider manuals, bulletins and hearing rules we opened and dated ourselves. Where the two disagree, the state's document is the one to trust — and Michigan is the example of why, because it still counts as covering while having rewritten what you must show to qualify.

• California — other diagnoses only. Coverage for weight loss ended January 1, 2026. GLP-1s stay covered for other approved uses.
• New York — other diagnoses only. Weight loss has never been a covered reason. Two GLP-1s are covered for other uses, both behind a high BMI.
• Pennsylvania — other diagnoses only. Coverage for overweight and obesity ended January 1, 2026. Saxenda is no longer covered for anything.
• Michigan — covers for weight loss. Coverage survived January 1, 2026, but only for morbid obesity after every other treatment has failed.
• Florida — does not cover. Weight control medications are a named exclusion, in a coverage policy still dated December 2017.
• Ohio — other diagnoses only. Obesity is a coded exclusion no one can request around. Wegovy is covered for heart and liver disease, not weight.
• North Carolina — covers for weight loss. Cut October 1, 2025 and restored ten weeks later. Now on, behind a BMI floor and a 5% renewal test.
• Georgia — does not cover. Weight-loss agents are a named exclusion. The one open door is Saxenda for ages 12 to 17, and it shuts at 18.
• Texas — other diagnoses only. Wegovy and Zepbound are covered, but obesity alone never qualifies — heart, liver or sleep apnea does.
• Illinois — does not cover. Excluded by rule. The state's own criteria file Wegovy, Zepbound and Saxenda as not covered agents.
• Washington — other diagnoses only. Excluded by rule for weight loss. Wegovy and Zepbound are covered only for heart, liver or sleep-apnea uses.
• Virginia — covers for weight loss. Covered with conditions: a BMI over 40, or over 37 with a named condition, after an older weight-loss drug is tried.
• Arizona — other diagnoses only. Excluded for weight loss. Wegovy is allowed for heart or liver disease; Zepbound for sleep apnea is denied.
• Massachusetts — other diagnoses only. Coverage for obesity ended July 3, 2026. Other approved uses stay covered; some members under 21 are excepted.
• New Jersey — other diagnoses only. Excluded by rule for obesity; a 2025 state study left it there. Wegovy and Zepbound are covered for other uses.
• Mississippi — covers for weight loss. Covered with prior authorization. Zepbound and Foundayo joined the preferred list on July 1, 2026.
• Missouri — covers for weight loss. Covered since January 2025, with Zepbound preferred. Wegovy is not covered for weight loss itself.
• Minnesota — covers for weight loss. Covers Saxenda, Wegovy and Zepbound with prior authorization. Renewal needs 5% weight loss.
• Wisconsin — covers for weight loss. A new weight management drug class opened July 1, 2026 with Zepbound preferred; eight older drugs dropped.
• Utah — other diagnoses only. Covered as a pilot from July 1, 2025 and ended June 30, 2026. Three comorbidity routes survive.
• Colorado — other diagnoses only. Weight loss is excluded by rule. Zepbound for sleep apnea and Wegovy for heart risk are the ways in.
• Kansas — covers for weight loss. Covers Wegovy and Zepbound as preferred. One statewide list binds all three KanCare plans.
• Maryland — other diagnoses only. Weight control is excluded by regulation. Wegovy for heart risk and Zepbound for sleep apnea are covered.
• Tennessee — covers for weight loss. Covered since August 1, 2025. Wegovy and Zepbound are preferred; older appetite drugs need no approval.
• Indiana — other diagnoses only. Excluded by rule for adults. Sleep apnea, heart risk and liver disease are the doors, and under-21 has its own.
• Delaware — covers for weight loss. Covers Wegovy and Zepbound as preferred, and has just moved the promise out of its State Plan.
• South Carolina — other diagnoses only. Removed GLP-1s for obesity from its drug list on December 31, 2025. Wegovy survives for heart and liver.
• Louisiana — other diagnoses only. Covers Wegovy for heart and liver, Zepbound for sleep apnea, and makes the patient sign an agreement.
• Alabama — other diagnoses only. Its drug list says it in a footnote: Wegovy and Zepbound are non-covered for weight reduction.
• Kentucky — other diagnoses only. No anti-obesity class on its drug list at all. Wegovy and Zepbound have their own criteria instead.
• Oregon — other diagnoses only. Excludes these drugs from its Prioritized List of Health Services entirely, not from a drug list.
• Oklahoma — other diagnoses only. Calls the category adiposity-based chronic disease, then closes the obesity-alone door three times over.
• Connecticut — other diagnoses only. Gated the GLP-1s to diabetes, then added two cheap oral weight-loss drugs on the same day.
• Rhode Island — other diagnoses only. From October 1, 2026, four GLP-1s are no longer covered for weight loss. Other uses need a new approval.
• Alaska — does not cover. The pharmacy manual excludes obesity drugs by name; the statewide drug list carries GLP-1s for diabetes only.
• Arkansas — other diagnoses only. Weight loss alone is excluded; Wegovy is covered for heart risk and liver disease, Zepbound for sleep apnea.
• Hawaii — depends on your plan. Hawaii sets no statewide drug list; coverage depends on which of five QUEST health plans a member is in.
• Idaho — does not cover. No anti-obesity drug appears on the current statewide list; the diabetes GLP-1s are covered for diabetes only.
• Iowa — other diagnoses only. Wegovy and Zepbound are Preferred on the drug list, but its own footnote excludes the weight-loss indication.
• Maine — other diagnoses only. Wegovy is covered for heart risk and a liver condition, Zepbound for sleep apnea. Weight loss stays excluded.
• Montana — other diagnoses only. The standard drug list never names Wegovy or Zepbound; a separate pathway covers each for a non-obesity reason.
• Nebraska — other diagnoses only. Both drugs are off the standard list, each with its own pathway: Wegovy for heart risk, Zepbound for sleep apnea.
• Nevada — other diagnoses only. Weight-management drugs are excluded by the state manual. Wegovy for heart risk, Zepbound for sleep apnea.
• New Hampshire — other diagnoses only. Weight-loss coverage ended January 1, 2026. Heart risk, sleep apnea and MASH survive.
• New Mexico — does not cover. The state's own page lists Wegovy, Zepbound and Saxenda as not covered by New Mexico Medicaid.
• North Dakota — other diagnoses only. No obesity pathway at all. Wegovy only for heart risk, ages 55 to 74; Zepbound only for sleep apnea.
• South Dakota — other diagnoses only. Wegovy is MACE or MASH only and Zepbound OSA only. The drug list's own class name rules out weight loss.
• Vermont — other diagnoses only. The drug list excludes weight-loss drugs up front. Wegovy for heart risk and Zepbound for sleep apnea are covered.
• West Virginia — other diagnoses only. Weight loss is a non-covered service. Wegovy covers heart risk and MASH; Zepbound covers sleep apnea.
• Wyoming — other diagnoses only. Anorexiant products are excluded outright. Wegovy needs heart disease or MASH; Zepbound needs sleep apnea.

What it costs you

• Who handles the pharmacy benefit in Medicaid managed care?
• Why manufacturer savings cards exclude Medicaid
• What brand Zepbound costs if you pay cash
• When Medicaid still covers Wegovy or Zepbound for another use
• Zepbound for sleep apnea under Medicaid

Where this comes from

1. KFF, effective January 2026 — Open the document
2. 42 CFR §431.221(d) — www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-431/subpart-E

Your state's Medicaid posture is in the coverage matrix, and the appeal routes are on the procedures page. What individual insurers publish about these drugs — and the much smaller thing those documents settle about your own plan — is on the carrier pages.